kabutan

Nano Holdings, Inc.(4571) Summary

4571
TSE Growth
Nano Holdings, Inc.
146
JPY
-2
(-1.35%)
Dec 12, 3:30 pm JST
0.93
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
145
Dec 12, 10:21 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.99
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
148 JPY 0.95 USD
Previous Close Dec 11
148 JPY 0.94 USD
High Dec 12, 9:20 am
150 JPY 0.96 USD
Low Dec 12, 12:57 pm
145 JPY 0.93 USD
Volume
540,800
Trading Value
0.08B JPY 0.51M USD
VWAP
146.85 JPY 0.94 USD
Minimum Trading Value
14,600 JPY 93 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
284
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
444
1-Year High Oct 10, 2025
15,902
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 5,385,600
Nov 28, 2025 0 5,234,100
Nov 21, 2025 0 5,224,300
Nov 14, 2025 0 5,461,200
Nov 7, 2025 0 5,460,900
Company Profile
NANO MRNA Co., Ltd. is a biotech venture specializing in mRNA therapeutics. The company is expanding its pipeline through collaborations and partnerships, with high expectations for treating intractable cancers.
Sector
Pharmaceuticals
NANO MRNA Co., Ltd. has been developing innovative pharmaceuticals, primarily focusing on anticancer drugs that encapsulate small molecules and other medicines within nanoparticles using micellar nanoparticle technology. In January 2023, the company shifted its business model to concentrate on mRNA therapeutics. mRNA therapeutics involve administering artificially manufactured mRNA to the body, enabling the expression of proteins encoded by the mRNA to prevent or treat diseases. The company is advancing multiple mRNA pipelines, including regenerative medicine for osteoarthritis of the knee, immune tolerance vaccines, and preventive vaccines for infectious diseases. NANO MRNA conducts research and development up to the preclinical trial stage and then licenses out to pharmaceutical companies. The company actively pursues joint research with academia, pharmaceutical, and non-pharmaceutical companies to expand its pipeline of new candidates. In addition to mRNA, NANO MRNA continues to develop brain tumor treatments and siRNA drugs targeting transcription factors. The company aims to establish a development system rivaling major pharmaceutical companies and create innovative medicines.